It's also recommended that clinicians discontinue the drug in patients with symptoms of liver injury. ... A drug safety communication about the risk of name confusion between ado-trastuzumab emtansine (Kadcyla) and trastuzumab (Herceptin).
The drug's safety and efficacy were evaluated in a clinical trial with more than 14,000 patients, in which it showed similar ability to warfarin in preventing stroke. ... Given the conflicting nature of the existing research findings on this issue, the
Caleb Alexander, MD, co-director of the Johns Hopkins School of Public Health Center for Drug Safety and Effectiveness in Baltimore. ... educated about the risks and benefits and if you can effectively monitor for safety.
a drug safety expert and consultant in Chapel Hill, N.C. ... Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol.
When meeting with Rep. Earl Blumenauer (D-OR), Ms. Blank and ACP Resident/Fellow Member Joel Burnett, MD, led discussions on prescription drug pricing and physician workforce issues. ... I don't have any problems with that,” although the downside is
But at this point, he noted, the drug remains costly for many patients. ... Food and Drug Administration. FDA Drug Safety Communication: Safety review of post-market reports of serious bleeding events with the anticoagulant Pradaxa (dabigatran etexilate
Photo by ThinkStock. A drug safety communication that canagliflozin (Invokana, Invokamet) causes an increased risk of leg and foot amputations. ... A drug safety communication about gadolinium-based contrast agents for MRI. An FDA review, initiated in
Phillips, who is the John A. Oates Chair in Clinical Research and professor of medicine and pharmacology and of pathology, microbiology, and immunology at the Center for Drug Safety and Immunology
A drug safety communication regarding known side effects of hydroxychloroquine and chloroquine. ... The drug is contraindicated in patients with known allergy or hypersensitivity to rabbits or rabbit proteins.
A drug safety communication that hepatitis C medicines have led to rare cases of worsening liver function or liver failure in some patients. ... The drug was originally approved in 2014 to treat adults with idiopathic pulmonary fibrosis.